Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03144037 · ClinicalTrials.gov registry record
Adherence of Hispanic / Latina Breast Cancer - Patients to Adjuvant Aromatase Inhibitors
A clinical trial, sponsored by Texas Tech University Health Sciences Center, El Paso.
- Completed
- Registry status
- 152
- Enrollment target
NCT03144037 is a clinical trial that has completed, run by Texas Tech University Health Sciences Center, El Paso. The registered enrollment target is 152 participants.
The verdict
NCT03144037 has completed, sponsored by Texas Tech University Health Sciences Center, El Paso.
- COMPLETED
- Registry status
- 152 participants
- Enrollment target
Study Summary
This is an observational trial designed to assess prospectively the adherence rate to AIs among women with invasive breast cancer (stages I-III) currently receiving AI adjuvant therapy after standard local and systemic therapy. We will study adherence by administrating the 8-item Morisky Medication Adherence Scale (MMAS - 8).
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 152 participants |
| Start Date | 2017-04-26 |
| Est. Completion | 2021-03-19 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03144037
The ClinicalTrials.gov registry entry for NCT03144037 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 152 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Texas Tech University Health Sciences Center, El Paso, which has 35 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT03144037 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03144037 about?
NCT03144037 is a clinical study titled "Adherence of Hispanic / Latina Breast Cancer - Patients to Adjuvant Aromatase Inhibitors". This is an observational trial designed to assess prospectively the adherence rate to AIs among women with invasive breast cancer (stages I-III) currently receiving AI adjuvant therapy after standard local and systemic therapy. We will study adherence by administrating the 8-item Morisky Medication ...
What is the current status of trial NCT03144037?
This trial is currently completed. The enrollment target is 152 participants. The study started on 2017-04-26. Estimated completion is 2021-03-19.
Who is sponsoring clinical trial NCT03144037?
This trial is sponsored by Texas Tech University Health Sciences Center, El Paso, which has 35 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.